51 related articles for article (PubMed ID: 9041050)
1. Osteoblastic proliferation in bone biopsies from patients with end-stage chronic renal failure.
Serrano S; Mariñoso ML; Torres A; Lorenzo V; Keysers U; Lloreta J; Nacher M; Garcia C; Ballester J; Diez A; Aubia J
J Bone Miner Res; 1997 Feb; 12(2):191-9. PubMed ID: 9041050
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of bone formation in osteoporosis patients treated with fluoride associated with increased DNA synthesis by osteoblastic cells in vitro.
Marie PJ; De Vernejoul MC; Lomri A
J Bone Miner Res; 1992 Jan; 7(1):103-13. PubMed ID: 1549953
[TBL] [Abstract][Full Text] [Related]
3. Plasma insulin-like growth factor-1 and bone formation parameters in predialysis chronic renal failure.
Coen G; Mazzaferro S; Ballanti P; Bonucci E; Bondatti F; Pasquali M; Perruzza I; Manni M; Sardella D
Miner Electrolyte Metab; 1991; 17(3):153-9. PubMed ID: 1779936
[TBL] [Abstract][Full Text] [Related]
4. [Bone histology in postmenopausal osteoporosis--variations in cellular activity].
Lozo P; Krpan D; Krvavica A; Vukelić Baturić T; Fistonić I; Kusec V
Acta Med Croatica; 2004; 58(1):5-11. PubMed ID: 15125387
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone.
Iwasaki-Ishizuka Y; Yamato H; Nii-Kono T; Kurokawa K; Fukagawa M
Nephrol Dial Transplant; 2005 Sep; 20(9):1904-11. PubMed ID: 15985520
[TBL] [Abstract][Full Text] [Related]
6. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies.
Chavassieux PM; Arlot ME; Roux JP; Portero N; Daifotis A; Yates AJ; Hamdy NA; Malice MP; Freedholm D; Meunier PJ
J Bone Miner Res; 2000 Apr; 15(4):754-62. PubMed ID: 10780867
[TBL] [Abstract][Full Text] [Related]
7. Decreased DNA synthesis by cultured osteoblastic cells in eugonadal osteoporotic men with defective bone formation.
Marie PJ; de Vernejoul MC; Connes D; Hott M
J Clin Invest; 1991 Oct; 88(4):1167-72. PubMed ID: 1918371
[TBL] [Abstract][Full Text] [Related]
8. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers.
Hauge EM; Qvesel D; Eriksen EF; Mosekilde L; Melsen F
J Bone Miner Res; 2001 Sep; 16(9):1575-82. PubMed ID: 11547826
[TBL] [Abstract][Full Text] [Related]
9. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
[TBL] [Abstract][Full Text] [Related]
10. Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population.
Andress DL; Maloney NA; Endres DB; Sherrard DJ
J Bone Miner Res; 1986 Oct; 1(5):391-8. PubMed ID: 3503554
[TBL] [Abstract][Full Text] [Related]
11. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients.
Ureña P; Ferreira A; Kung VT; Morieux C; Simon P; Ang KS; Souberbielle JC; Segre GV; Drüeke TB; De Vernejoul MC
J Bone Miner Res; 1995 Jun; 10(6):932-9. PubMed ID: 7572317
[TBL] [Abstract][Full Text] [Related]
12. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
Borah B; Ritman EL; Dufresne TE; Jorgensen SM; Liu S; Sacha J; Phipps RJ; Turner RT
Bone; 2005 Jul; 37(1):1-9. PubMed ID: 15894527
[TBL] [Abstract][Full Text] [Related]
13. Serum IGF 1 is low and correlated with osteoblastic surface in idiopathic osteoporosis.
Reed BY; Zerwekh JE; Sakhaee K; Breslau NA; Gottschalk F; Pak CY
J Bone Miner Res; 1995 Aug; 10(8):1218-24. PubMed ID: 8585426
[TBL] [Abstract][Full Text] [Related]
14. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment.
Coen G; Mazzaferro S; Costantini S; Ballanti P; Carrieri MP; Giordano R; Smacchi A; Sardella D; Bonucci E; Taggi F
Miner Electrolyte Metab; 1989; 15(5):295-302. PubMed ID: 2811788
[TBL] [Abstract][Full Text] [Related]
15. The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.
Christiansen P
APMIS Suppl; 2001; (102):1-52. PubMed ID: 11419022
[TBL] [Abstract][Full Text] [Related]
16. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
[TBL] [Abstract][Full Text] [Related]
17. Evidence for reduced bone formation surface relative to bone resorption surface in female femoral fragility fracture patients.
Tsangari H; Findlay DM; Zannettino AC; Pan B; Kuliwaba JS; Fazzalari NL
Bone; 2006 Dec; 39(6):1226-35. PubMed ID: 16926124
[TBL] [Abstract][Full Text] [Related]
18. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study.
Chapurlat RD; Arlot M; Burt-Pichat B; Chavassieux P; Roux JP; Portero-Muzy N; Delmas PD
J Bone Miner Res; 2007 Oct; 22(10):1502-9. PubMed ID: 17824840
[TBL] [Abstract][Full Text] [Related]
19. Calcitropic hormonal status in north Indian patients with end-stage renal disease.
Singh AK; Avula S; Kher V; Rao DS; Mithal A
Natl Med J India; 1999; 12(5):202-7. PubMed ID: 10612998
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of bone Gla-protein in normal humans and in patients with chronic renal failure.
Sugimoto K; Dohi Y; Dohi K; Yonemasu K; Fujimoto J; Kanauchi M; Yamanaka F; Moriyama T; Ishikawa H
Miner Electrolyte Metab; 1987; 13(3):152-7. PubMed ID: 3498115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
